Across the universe of K-RAS mutations in non-small-cell-lung cancer

Current Pharmaceutical Design

Volumn 20, Issue 24, 2014, Pages 3933-3943

  Piva, Sheila ^a   Ganzinelli, Monica ^a,b   Garassino, Marina Chiara ^c   Caiola, Elisa ^b   Farina, Gabriella ^a   Broggini, Massimo ^b   Marabese, Mirko ^b  

^a Oncology Department   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Animal model; Cell response; K RAS; Mutation; Non small cell lung cancer; Prognosis; Synthetic lethality

Indexed keywords

GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P16; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CELL DAMAGE; CELL DEATH; CELL FUNCTION; GENE MUTATION; GENE SILENCING; HUMAN; IONIZING RADIATION; LETHALITY; LUNG NON SMALL CELL CANCER; META ANALYSIS; NONHUMAN; ONCOGENE RAS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; RAS PROTEINS;

EID: 84903954150     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660761     Document Type: Article

References (63)

1. Okudela K, Woo T, Kitamura H. KRAS gene mutations in lung cancer: particulars established and issues unresolved. Pathol Int 2010; 60: 651-660.
2. Hancock JF. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 2003; 4: 373-384.
3. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.
4. Rodriguez-Viciana P, Sabatier C, McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 2004; 24: 4943-4954.
5. Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 2009; 6: 528-534.
6. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359: 1367-1380.
7. Mao C, Qiu L-X, Liao R-Y, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies. Lung Cancer 2010; 69: 272-278.
8. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010; 28: 4769-4777.
9. You M, Wang Y, Stoner G, et al. Parental bias of Ki-ras oncogenes detected in lung tumors from mouse hybrids. Proc Natl Acad Sci USA 1992; 89: 5804-5808.
10. Granville CA, Memmott RM, Balogh A, et al. A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. PLoS ONE 2009; 4.
11. Stinn W, Teredesai A, Kuhl P, et al. Mechanisms involved in A/J mouse lung tumorigenesis induced by inhalation of an environmental tobacco smoke surrogate. Inhal Toxicol 2005; 17: 263-276.
12. Wang Y, Zhang Z, Yao R, Jia D, Wang D, Lubet RA, You M. Prevention of lung cancer progression by bexarotene in mouse models. Oncogene 2006; 25: 1320-1329.
13. Garassino MC, Marabese M, Rusconi P, et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol 2011; 22: 235-237.
14. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410: 1111-1116.
15. DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nature Protocols 2009; 4: 1064-1072.
16. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003; 4: 111-120.
17. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of onco-genic K-ras. Genes Development 2001; 15: 3243-3248.
18. Meuwissen R, Linn SC, Van Der Valk M, Mooi WJ, Berns A. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-ras oncogene. Oncogene 2001; 20: 6551-6558.
19. Winslow MM, Dayton TL, Verhaak RGW, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 2011; 473: 101-104.
20. Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene 2007; 26: 6896-6904.
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
22. Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689-698.
23. Garber K. Synthetic lethality: killing cancer with cancer. J Natl Cancer Inst 2002; 94: 1666-1668.
24. Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011; 10: 351-364.
25. Ferrari E, Lucca C, Foiani M. A lethal combination for cancer cells: synthetic lethality screenings for drug discovery. Eur J Cancer 2010; 46: 2889-2895.
26. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008; 9: 517-531.
27. Sawyers CL. Finding and drugging the vulnerabilities of RAS-dependent cancers. Cell 2009; 137: 796-798.
28. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 2001; 19: 940-945.
29. Scholl C, Frohling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009; 137: 821-834.
30. Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009; 462: 104-107.
31. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462: 108-112.
32. Puyol M, MartÃn A, Dubus P, et al. A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma. Cancer Cell 2010; 18: 63-73.
33. Gilad O, Nabet BY, Ragland RL, et al. Combining ATR suppression with oncogenic ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res 2010; 70: 9693-9702.
34. Huang S, Ren X, Wang L, Zhang L, Wu X. Lung-cancer chemo-prevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo. Cancer Prevention Research 2011; 4: 666-673.
35. Choi JA, Park MT, Kang CM, et al. Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways. Oncogene 2004; 23: 9-20.
36. Konstantinidou G, Bey EA, Rabellino A, et al. Dual phosphoinosi-tide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Research 2009; 69: 7644-7652.
37. Park IH, Kim JY, Jung JI, Han JY. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Investigational New Drugs 2010; 28: 791-799.
38. Jeong SH, Wu HG, Park WY. LIN28B confers radio-resistance through the posttranscriptional control of KRAS. Exp Mol Med 2009; 41: 912-918.
39. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA 2010; 304: 1812-1820.
40. American-Cancer-Society. Cancer Facts & Figures 2011. American Cancer Society: Atlanta 2011.
41. Paone G, De Angelis G, Munno R, et al. Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1. Eur Respir J 1995; 8: 1136-1140.
42. West H, Harpole D, Travis W. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest 2009; 136: 1112-1128.
43. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009; 6: 352-366.
44. Trial watch: Adaptive BATTLE trial uses biomarkers to guide lung cancer treatment. Nat Rev Drug Discov 2010; 9: 423-423.
45. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987; 317: 929-935.
46. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009; 6: 201-205.
47. Garassino MC, Borgonovo K, Rossi A, et al. Biological and Clinical Features in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-analysis. Anticancer Res 2009; 29: 2691-2701.
48. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005; 92: 131-139.
49. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and me-tastatic colorectal cancer. Lancet Oncol 2008; 9: 962-972.
50. Ahrendt SA, Yang SC, Wu L, et al. Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: preliminary results of a prospective study. J Thorac Cardio-vasc Surg 2002; 123: 466-473; discussion 473-4.
51. Jassem J, Jassem E, Jakobkiewicz-Banecka J, et al. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma. Cancer 2004; 100: 1951-1960.
52. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cis-platin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597.
53. Marchetti A, Milella M, Felicioni L, et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 2009; 11: 1084-1092.
54. Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol 2013; 31: 1112-1121.
55. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 519-527.
56. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892-5899.
57. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
58. Dahabreh IJ, Linardou H, Kosmidis P, Bafaloukos D, Murray S. EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Ann Oncol 2011; 22: 545-552.
59. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010; 28: 744-752.
60. Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second line treatment of patients with advanced non-small-cell lung cancer and wild type EGFR tumors (TAILOR): a randomised controlled trial. Lancet Oncol 2013; 14: 38-47.
61. Marabese M, Rulli E, Bettini A, et al. KRAS mutational status impact progression-free survival of patients treated with platinum-based chemotherapy in NSCLC. Mol Cancer Therapeut 2011; 10: B77.
62. Riely GJ, Brahmer JR, Planchard D, et al. A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. ASCO Meeting Abstracts 2012; 30: 7531.
63. Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013; 14: 38-47.